Clear Catheter Systems Wins Prestigious International Innovation Award

  2013 “Innovations in Cardiovascular Interventions” Top Prize goes to Medical Device Start-up for PleuraFlow Clear Catheter Systems, Inc., announced today it has won the 2013 Innovations in Cardiovascular Interventions (ICI) Best Start-Up Innovation Award for its medical device, PleuraFlow®, a novel system that optimally evacuates blood and fluid after surgery to speed recovery and improve patient outcomes in the ICU during the initial critical hours after heart surgery. 

Bleeding after heart surgery: Better out than in!

All patients bleed in the early hours after heart surgery. The post-operative blood shed into the chest is drained through chest tubes and collected in drainage canisters. For some this is just a few hundred cc’s and then it stops. For others it can be more than a liter. In these early hours after surgery great efforts are taken to support the patient until coagulation is restored and bleeding subsides.

What’s your Protocol?

Proactive Protocols to Reduce Complications After Cardiac Surgery Improving outcomes and reducing costs is a continual effort in modern healthcare. For heart surgery patients, a good place to start is by focusing on something that is common to nearly all patients recovering. All cardiac surgery patients have some degree of bleeding postoperatively, and chest tubes are used to evacuate this blood from the pleural and/or pericardial spaces.

The PleuraFlow Active Tube Clearance System Initial Clinical Experience in Adult Cardiac Surgery

Louis P. Perraut, Michel Pellerin, Michel Carrier, Raymond Cartier, Denis Bouchard, Philippe Demers, Edward M. Boyle. Innovations 2012; 7(5):354-358 This initial clincial experience found found that the PleuraFlow system was easily incorporated into the postoperative workflow of managing the drainage of patients after heart surgery. The PleuraFlow system was easily understood by the nurses in the ICU and the use of the device was obvious to learn, efficient, and effective.